(MT Newswires) Stéphane Bancel, CEO of Moderna, announces a significant breakthrough for cancer patients, particularly those suffering from melanoma. Moderna uses its technology to develop personalized treatments, where each patient receives a specific drug tailored to the DNA of his or her cancer cells. Data show that the drug developed by Moderna, compared with the best treatment currently available, Merck's Keytruda, improved progression-free survival by 44% after two years, and this improvement reached 49% after three years.

Bloomberg videos